Prostate Hypoxia FAZA

University Health Network, Toronto18 enrolled

Overview

The purpose of this study is to look for low levels of oxygen (hypoxia) in prostate cancer using a special x-ray test called a positron emission tomography (PET)scan. Hypoxia may have an effect on how prostate cancer grows and responds to treatments like radiotherapy and chemotherapy. The use of PET scans to measure hypoxia may be better and simpler than the methods used previously.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Enrollment

Conditions

Prostate Cancer

Interventions

18F-Fluoroazomycin Arabinoside (18F-FAZA)OTHER

PET scan with the radiolabelled tracer 18F-FAZA

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age =\> 18 years * Histologic diagnosis of adenocarcinoma of the prostate * Bulky intermediate risk, high risk or metastatic prostate cancer Bulky intermediate risk: cT1-2 with \>50% of diagnostic biopsy cores containing cancer and Gleason 6 or 7 and prostate specific antigen (PSA) \>10 and ≤20 OR High risk: cT1-2 with Gleason score ≥8; or cT1-2 with PSA \>20; or cT3 OR N+ and/or M1 disease OR Newly diagnosed hormone-refractory prostate cancer - Intention to treat using radiotherapy +/- concurrent and adjuvant hormonal therapy * Intention to treat with radiotherapy, hormonal therapy, other systemic treatment for prostate cancer, or a combination of these according to the Princess Margaret Genitourinary Site policies. * Previous or concurrent anti-cancer therapy for the PET FAZA target lesion allowed * Ability to provide written informed consent to participate in the study Exclusion Criteria: * Inability to lie supine for more than 60 minutes * Patients taking the drug disulfiram (Antabuse) * Contraindications for MRI: only applicable in cases where the PET FAZA target lesion is identified as the prostate gland. Patients with target lesions at other anatomic sites will not undergo MR imaging. * Patients weighing \> 136 kg

Locations (1)

University Health Network

Toronto, Ontario, Canada

Outcomes

Primary Outcomes

Number of patients treated with the PET tracer FAZA to image primary tumor hypoxia in patients with prostate cancer prior to treatment with radiotherapy +/- concurrent and adjuvant hormonal therapy

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.